Eledon Pharmaceuticals, Inc. is rated a Strong Buy following positive phase 2 BESTOW results for tegoprubart. Read more on ELDN stock here.

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of FDA-approved C3 inhibitors that targets the root of the complement system can ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

FDA proposes using a well-supported mechanistic rationale plus natural history comparators to generate substantial evidence when randomized trials are infeasible for ultra-rare populations.

Oscar Onley is stepping into a new phase of his career as he lines up for his first race with Ineos Grenadiers at Volta ao Algarve on Wednesday. However, the 23-year-old isn't heading into the ...

FDA breakthrough therapy designation targets HPV-unrelated recurrent/metastatic HNSCC after progression on platinum-based chemotherapy and PD-1/PD-L1 inhibitors, aiming to accelerate development and ...

Regulatory clearance establishes the first EGFR-targeted regimen with monthly maintenance dosing, reducing chair time and infusion-center burden versus prior biweekly IV administration. PALOMA-3 ...